stockrowXencor, Inc.
XNCR Healthcare Biotechnology
Xencor, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $125.6 million, up 13.7% from fiscal 2024.
- Revenue
- +17.5%
- EPS
- +29.3%
- Free cash flow
- −52.9%
Quarter to June 2026, against a year earlier
Follow XNCR
Alert me
Xencor, Inc. (XNCR) Return on invested capital
Xencor, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −288.7%, down 235.3 percentage points from fiscal 2025 (−53.4%). Over the past ten years it has ranged from −53.4% (fiscal 2025) to 15.0% (fiscal 2016) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −53.4% | (20.63) |
| FY2024 | −32.8% | (0.73) |
| FY2023 | −32.1% | (0.66) |
| FY2022 | −31.4% | (37.73) |
| FY2021 | 6.31% | 6.31 |
| FY2020 | 0.00% | (11.65) |
| FY2019 | 11.7% | 33.47 |
| FY2018 | −21.8% | 7.37 |
| FY2017 | −29.2% | (44.16) |
| FY2016 | 15.0% | 32.34 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| ADMA ADMA Biologics Inc compare | 48.0% |
| RCUS Arcus Biosciences, Inc. compare | 0.00% |
| MBX MBX Biosciences, Inc. compare | 0.00% |
| PHVS Pharvaris N.V. compare | 0.00% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | −21.3% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −23.1% |
| RXRX Recursion Pharmaceuticals, Inc. compare | −88.5% |
| XNCR Xencor, Inc. | −288.7% |
| BEAM Beam Therapeutics Inc. compare | −2,676.9% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on XNCR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement